Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Humanigen Inc
(NQ:
HGEN
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Jul 25, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Humanigen Inc
< Previous
1
2
3
4
Next >
Investor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Humanigen, Inc. (HGEN) Investors of Class Action and Encourages Investors to Actively Participate
September 02, 2022
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
HGEN Shareholder Update: Robbins LLP Reminds Investors of Class Action Filed Against Humanigen, Inc. (HGEN)
August 30, 2022
From
Robbins LLP
Via
Business Wire
HUMANIGEN ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Humanigen, Inc. and Encourages Investors to Contact the Firm
August 29, 2022
From
Bragar Eagel & Squire, P.C.
Via
Business Wire
Humanigen, Inc. Shareholder Alert: Robbins LLP Informs Investors of Class Action Against Humanigen, Inc. (HGEN)
August 29, 2022
From
Robbins LLP
Via
Business Wire
EQUITY ALERT: Rosen Law Firm Encourages Humanigen, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – HGEN
August 29, 2022
From
Rosen Law Firm
Via
Business Wire
INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in Humanigen, Inc. with Losses of $100,000 to Contact the Firm
August 29, 2022
From
The Schall Law Firm
Via
Business Wire
INVESTOR ACTION REMINDER: The Schall Law Firm Encourages Investors in Humanigen, Inc. with Losses of $100,000 to Contact the Firm
August 27, 2022
From
The Schall Law Firm
Via
Business Wire
NASDAQ:HGEN Shareholder Notice: Investigation over Possible Securities Laws Violations by Humanigen, Inc.
August 17, 2022
San Diego, CA -- (SBWIRE) -- 08/17/2022 -- Humanigen, Inc. is under investigation over potential securities laws violations in connection with certain financial statements.
Via
SBWire
Humanigen Reports Second Quarter 2022 Financial Results
August 12, 2022
From
Humanigen, Inc.
Via
Business Wire
Humanigen Implements Strategic Realignment of Pipeline and Resources to Achieve Key Clinical Milestones
July 26, 2022
Short Hills, New Jersey--(Newsfile Corp. - July 26, 2022) - Humanigen, Inc. (NASDAQ: HGEN) ("Humanigen"), a clinical-stage biopharmaceutical company focused...
Via
Newsfile
INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in Humanigen, Inc. with Losses of $100,000 to Contact the Firm
July 19, 2022
From
The Schall Law Firm
Via
Business Wire
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Humanigen, Inc. with Losses of $100,000 to Contact the Firm
July 18, 2022
From
The Schall Law Firm
Via
Business Wire
Humanigen Receives Preliminary Topline Data From NIH/NIAID Study of Lenzilumab in ACTIV-5/BET-B
July 12, 2022
From
Humanigen, Inc.
Via
Business Wire
Humanigen Announces Peer-Reviewed Publication in Thorax Supporting Early Treatment of Hospitalized COVID-19 Patients with Lenzilumab Guided by C-Reactive Protein
July 06, 2022
From
Humanigen, Inc.
Via
Business Wire
NIH/NIAID Locks ACTIV-5/BET-B Database
June 30, 2022
From
Humanigen, Inc.
Via
Business Wire
Humanigen Enters into Agreement with PCI Pharma Services as Part of Preparations for Commercialization in the United Kingdom
June 16, 2022
From
Humanigen, Inc.
Via
Business Wire
Humanigen Announces Participation and Presentation at Multiple Conferences in June
June 03, 2022
From
Humanigen, Inc.
Via
Business Wire
Humanigen Announces Participation and Presentation at H.C. Wainwright Global Investment Conference
May 24, 2022
From
Humanigen, Inc.
Via
Business Wire
Humanigen Reports First Quarter 2022 Financial Results
May 05, 2022
From
Humanigen, Inc.
Via
Business Wire
Humanigen Announces Participation and Presentation at Multiple Conferences in May
May 04, 2022
From
Humanigen, Inc.
Via
Business Wire
Humanigen Announces Peer-Reviewed Publication Demonstrating the Potential Clinical and Economic Benefits of Lenzilumab from the Perspective of the NHS
April 19, 2022
From
Humanigen, Inc.
Via
Business Wire
Humanigen to Present and Participate at Multiple Investor Events in March
February 25, 2022
From
Humanigen, Inc.
Via
Business Wire
Humanigen to Present at BIO CEO & Investor Conference
February 11, 2022
From
Humanigen, Inc.
Via
Business Wire
Humanigen Launches Managed Access Program for Lenzilumab
February 09, 2022
From
Humanigen, Inc.
Via
Business Wire
Humanigen and Cenexi Announce Collaboration to Manufacture Lenzilumab in France
February 08, 2022
From
Humanigen, Inc.
Via
Business Wire
Humanigen Announces Peer-Reviewed Publication in The Journal of Medical Economics Demonstrating the Clinical and Economic Benefits of Lenzilumab
January 18, 2022
From
Humanigen, Inc.
Via
Business Wire
Humanigen Aligns with FDA on Potential Registration Phase 3 Study for Lenzilumab with CAR-T
January 10, 2022
From
Humanigen, Inc.
Via
Business Wire
Humanigen Announces Target Enrollment in Phase 2/3 ACTIV-5/BET-B Trial of Lenzilumab for the Treatment of COVID-19 has Been Achieved
January 05, 2022
From
Humanigen, Inc.
Via
Business Wire
Humanigen to Present at Investor Conferences January 7 and 13, 2022
January 04, 2022
From
Humanigen, Inc.
Via
Business Wire
Lenzilumab Treatment Response in Hospitalized COVID-19 Patients Correlates with C-Reactive Protein Levels
January 03, 2022
From
Humanigen, Inc.
Via
Business Wire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.